Henlius Posts 27% Revenue Growth, Expands Global Oncology Footprint — Shanghai Henlius Biotech, Inc.

Event summary

Henlius reported 27.3% YoY revenue growth to RMB 3.5882 billion in H1 2026, with net profit up 10.3% YoY to RMB 430.4 million.
Ex-China sales revenue surged 159.4% YoY to RMB 105.3 million, with product profit from these markets more than quadrupling.
Serplulimab (Hetronifly®) gained NMPA approval as the world's first anti-PD-1 mAb for perioperative gastric cancer treatment.
HANBEIYOU became the first Chinese-developed pertuzumab biosimilar approved in China, the U.S., and the EU.
R&D expenditure increased 45.7% YoY to RMB 1.4507 billion, supporting over 50 early-stage pipeline molecules.

The big picture

Henlius is executing on its 'Globalization 2.0' strategy, leveraging biosimilar cash flows to fund innovative oncology assets. The company's ability to secure first-in-class regulatory approvals positions it as a competitor to Western biopharma giants. With 10 products approved in over 60 countries and a growing pipeline of differentiated assets, Henlius is emerging as a significant player in the global biopharmaceutical market.

What we're watching

Global Expansion Pace: Whether Henlius can sustain its 159.4% YoY growth in ex-China markets through continued regulatory approvals and strategic partnerships.
Pipeline Validation: How the clinical progress of key assets like HLX43 and dulpatatug will impact Henlius' long-term growth prospects.
Regulatory Strategy: The effectiveness of Henlius' parallel China-U.S. development pathway for biosimilars in accelerating global commercialization.